Class IIITerminatedD-1386-2019
Drug recall · June 19, 2019
Ondansetron Injection recall
Why: Failed Impurities/Degradation Specifications.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20
- Lots / codes
Lot #: 6018699, Exp. 12/2021
- Quantity
- 11,981 units
- Company
- Fresenius Kabi USA, LLC, Grand Island, NY
- Distribution
- Nationwide within the United States
- Initiated
- May 22, 2019 · Voluntary: Firm initiated
- Classified
- June 14, 2019
- Reported
- June 19, 2019
- Ended
- January 28, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ondansetron
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.